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Abs tr ac t
Autoantibodies (Ab) against the thyroid-stimulating hormone
receptor (TSHR) are frequently found in autoimmune thyroid
disease (AITD). Autoantibodies to the TSHR (anti-TSHR-Ab) may
mimic or block the action of TSH or be functionally neutral.
Measurement of anti-TSHR-Ab can be done either via competitive-binding immunoassays or with functional cell-based bioassays. Antibody-binding assays do not assess anti-TSHR-Ab
functionality, but rather measure the concentration of total
anti-TSHR binding activity. In contrast, functional cell-based
bioassays indicate whether anti-TSHR-Ab have stimulatory or
blocking activity. Historically bioassays for anti-TSHR-Ab were
research tools and were used to study the pathophysiology of
Graves’ disease and Hashimoto’s thyroiditis. In the past, bioassays for anti-TSHR-Abs were laborious and time-consuming
and varied widely in performance from laboratory to laboratory.
Recent advances in the development of cell-based assays, including the application of molecular engineering, have led to significant improvements that have enabled bioassays to be employed
routinely in clinical laboratories. The prevalence and functional
significance of TSHR blocking autoantibodies (TBAb) in autoimmune hypothyroidism has been less well investigated compared
to TSHR stimulating Ab. There is an increasing body of data,
however, that demonstrate the clinical utility and relevance of
TBAb, and thus the importance of TBAb bioassays, in the diagnosis and management of patients with AITD. In the present
review, we summarize the different methods used to measure
TBAb, and discuss their prevalence and clinical relevance.

GD
HT
IgG
L-T4
LH-CG
MAb
Mc4
RAI
RIA
TBII
TBAb
TSAb
TSH

Graves’ disease
Hashimoto’s thyroiditis
Immunoglobulin G
Levothyroxine
Luteinizing hormone-choriongonadotropin
Monoclonal antibody
Mutant chimeric 4
Radioactive iodine
Radio-immunoassay
TSHR-binding inhibitory immunoglobulin
TSHR-blocking autoantibodies
TSHR-stimulating autoantibodies
Thyroid-stimulating hormone
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T4
T3
TSHR
wt

Thyroxine
Triiodothyronine
TSH receptor
Wild-type

Introduction
Autoimmune thyroid diseases (AITD) are characterized through increased familial clustering, reduced DNASE1 gene expression,
CTLA-4 polymorphisms, and are strongly associated with the major
histocompatibility (MHC) complex [1–4]. However, autoantibodies to various thyroid antigens are the most important biomarkers
that are used to differentiate AITD from other thyroid conditions.
Whereas antibodies to thyroid peroxidase (TPO) and thyroglobulin
(Tg) neither play a major nor casual role in the pathophysiology of
AITD, antibodies to the TSHR play a unique role in the development
of autoimmune hyper- and hypothyroidism. Autoantibodies to the
TSHR (anti-TSHR-Ab) are directly involved in the pathophysiology
of Graves’ disease (GD) and Hashimoto’s thyroiditis (HT). GD is
caused by TSHR-stimulating antibodies (TSAb), which act as agonists by stimulating thyroid growth and thyroid hormone synthesis in an unregulated manner [5–7]. In contrast, blocking anti-TSHRAb (TBAb) acts as TSHR antagonists, which block the action of the
thyroid-stimulating hormone (TSH) and can cause the hypothyroidism of HT. Anti-TSHR-Ab can be detected either with immunoassays, which measure TSHR-binding inhibitory immunoglobulins
(TBII) [8] or with cell-based bioassays, which measure either TSAb
or TBAb [9]. The advantages and disadvantages of binding assays
versus functional bioassays for anti-TSHR-Ab, with special emphasis on TBAb, are shown in ▶Table 1.
Bioassays involve the measurement of signal transduction pathways mediated by binding of a ligand to the TSHR [10, 11]. Compared to TBII binding assays, cell-based bioassays are more sensitive in detecting low anti-TSHR-Ab concentrations and exclusively
differentiate between the anti-TSHR-Ab functionality [12, 13]. Historically bioassays that measure TSAb were based on measurement

of cAMP levels in cells using radio-immunoassays (RIA) [14–19].
More recently, non-radioactive methods to measure cAMP have
been used. In addition, cell lines that contain a cAMP-inducible reporter gene such as luciferase have been employed to measure
TSAb [20–23]. Bioassays that measure TSHR-blocking activity are
based on the same cell-based systems, but they detect the ability
of patient antisera to block TSH or TSAb-stimulated cAMP levels or
luciferase expression [23–25].
Most reviews of anti-TSHR-Ab have focused primarily on TSAb.
In the present, paper we will focus on TBAb. Compared to TSAb [26–
28], the measurement and clinical utility of functional TBAb have
been less well investigated. Many reports have studied the occurrence of TBAb in various autoimmune diseases associated with hypothyroidism such as autoimmune-induced atrophic thyroiditis or
primary myxedema [29–34]. The prevalence of TBAb in these various conditions is still controversial. Other investigations have focused on the role of TBAb in congenital and neonatal hypothyroidism associated with maternal AITD [31, 35–38]. The importance of
TBAb in congenital hypothyroidism, however, has been questioned.
Ever since it has been known that anti-TSHR-Ab exhibit different
functional activities it has been suspected that certain patients
might contain both TSAb and TBAb, and that this may explain certain clinical presentations. Recent evidence has proven that a patient can have both TSAb and TBAb by isolating separate monoclonal antibodies (MAb) with stimulatory and blocking activity from
the lymphocytes of the same patient [39, 40]. In addition, there has
been speculation that patients with GD may shift between stimulating and blocking antibodies as they transition from hyperthyroid
to hypothyroid and vice versa. The mechanism of transition from
TSAb to TBAb is most probably due to a different ratio between the
two functional autoantibodies; while the exact antigenic sites of the
TSHR against TBAb and TSAb are strongly overlapping and not completely defined. In the present paper, we will review the historical
and currently used assays used for the measurement of TBAb activity and discuss their clinical applications.

▶Table 1 Advantages and disadvantages of binding (TBII) Assays versus functional bioassay for TSHR blocking autoantibodies.

Binding Assays (TBII)

Advantages

Disadvantages

International standardization with reference material

Do not discriminate the functional antibody type

Easy handling and performance

Only measure antibody binding to the TSHR

M22 and KSAb1, human and mouse thyroid stimulating mAbs
respectively, have replaced bTSH in newer automated binding assays

TBII levels reflect total anti-TSHR-Ab

Commercially automated assays are available
Functional Bioassay

Measure the net sum of the functional activity

Absence of an international standard

Discriminate the functional antibody type, specifically identifying
TBAb *

More time consuming than TBII

Higher analytical sensitivity than binding assays (TBII)

Requires experienced laboratory technician

Newly developed bioassays: minimal handling of the cells, no IgG
purification, no serum starvation, no serum concentration

Not widely available

Predict fetal/neonatal risk for hypothyroidism in pregnant women with
active or treated AITD

Not automated yet

*  According to references [23, 25] and JP Banga, personal communication.
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Pathophysiology of Hashimoto’s
Thyroiditis
Hashimoto’s thyroiditis is the major cause of autoimmune hypothyroidism and GD is the primary cause of autoimmune hyperthyroidism.
Whereas the hyperthyroidism of GD is exclusively due to TSAb, there
are several mechanisms, by which hypothyroidism develops in HT. The
primary pathological basis of decreased thyroid hormone production
is related to immune-mediated apoptosis and cytolysis of thyrocytes.
Normal thyroid epithelial cells express a variety of death receptors including Fas and activation of the Fas-ligand-Fas signaling system contributes to the follicular cell destruction characteristic of HT. In addition, cytokine stimulation from antigen-presenting cells and Th1 cells
(IL-1) can induce functional Fas and also Fas ligand on thyroid follicular
cells which can lead to self-apoptosis [41]. Furthermore, the accumulation of activated T cells expressing Fas ligand may induce apoptosis
of thyrocytes directly by interacting with Fas on the cells [42].
The characteristic histopathological abnormalities of HT are profuse lymphocytic infiltration, lymphoid germinal centers, and destruction of thyroid follicles. Intrathyroidal lymphocytes are both T and 
B cells. Recent insight into the development of intrathyroidal germinal centers and lymph vessels suggests the importance of local production of chemokines [43]. B cells from thyroid tissue of patients with
HT are activated, as indicated by their ability to secrete thyroid antibodies spontaneously in vitro. Thus, the thyroid gland may be a major
site of thyroid Ab secretion. Anti-Tg and anti-TPO Ab of the appropriate IgG subclass have the potential to fix complement, and thus antibody-mediated complement-dependent cytotoxicity (CDC) may contribute to thyroid damage in some patients with HT [44]. More important may be the role of thyroid Ab secreting B cells in presenting thyroid antigen to the T cells, which react with processed thyroid antigens
and peptides derived from these antigens. These activated T cells secrete cytokines, which themselves activate a variety of other immune
cells. T cells have two roles in this disease: a role in Ab production (a
Th2 type of function) and a role in the apoptotic destruction of thyroid cells by activating cytotoxic T cells (a Th1 function) [45]. The Th1
CD4 +  lymphocytes, when stimulated by antigen, secrete interleukin-2 (IL-2), interferon gamma, and tumor necrosis factor-beta. In contrast, Th2 cells, when stimulated by antigens, secrete IL-4 and IL-5.
Both types of T cells are found in thyroid tissue of patients with HT, but
Th1 cells predominate [46, 47]. A T-cell clone that caused cytolysis of
autologous thyroid cells has been reported in a patient with HT [48].
Finally, in addition to the various mechanisms of thyroid cell death,
decreased thyroid hormone production in HT may be caused by TBAb
which rather than causing thyroid cell death, bind to the TSHR and interfere with the ability of thyrocytes to respond to TSH. The relative
contribution of all of these immunopathophysiological mechanisms
in HT varies from patient to patient.

Bioassays for TSHR-Blocking
Autoantibodies
Definition of blocking activity
Anti-TSHR-Ab that bind to the TSHR and neither activate the cyclic
AMP pathway nor stimulate thyroid hormone synthesis, but rather
Diana T et al. TSHR Blocking Antibodies. Horm Metab Res 2018; 50: 853–862

act as TSHR antagonists inhibiting the activation of signal transduction pathways, are defined as blocking anti-TSHR-Ab or TBAb [49, 50].

Historical methodology
Early bioassays for the detection of TBAb were based on the same
cell-based systems used for TSAb, including thyroid plasma membranes, thyroid tissue slices, and eventually cultured thyroid cells
[51–53]. In contrast to TSAb bioassays, TBAb bioassays detected the
ability of patient sera to block various concentration of bovine TSH
(bTSH) or TSAb-stimulated cAMP levels. Alternative TBAb assay systems were sought to address the limitations associated with using
thyroid tissue or primary thyroid cells. A major advance in the field
was the isolation of a cell line from normal rat thyroid (Fisher rat thyroid cell line, FRTL-5), which endogenously expressed the TSHR and
was TSH-dependent for growth [54]. Importantly, FRTL-5 cells retained the main features of normal thyroid functions, such as hormone response, iodide uptake and thyroglobulin synthesis and could
be maintained over the relatively long culture period which used by
several investigators [33, 49, 54].
Further improvement in the detection of blocking activity was
achieved with a luminescent bioassay for TBAb utilizing the CHOK1 cell line (named lulu * ) stably transfected with the human TSHR
and a luciferase gene under control of a promoter with a cAMP responsive element [24]. Using CHO lulu cells and a luminescent assay
for TBAb, twelve samples, previously shown to contain TBAb by an
established method quantifying cAMP by RIA, were also positive
by the luciferase-based assay [24]. The specificity of this assay was
excellent in that 20/20 patients with systemic lupus erythematosus, 13/14 with rheumatoid arthritis and 12/12 with multinodular
goiter were negative for TBAb. Bioassays using such engineered
CHO cells have the advantage of expressing the human TSHR and
they require less cumbersome procedures for cell culture [55].
Another CHO cell line was generated for the measurement of
TBAb that stably expressed a TSHR/LH-CG receptor construct that
was reported to have a reduced response to most TSAb [56]. This
Mc1 + 2 TSHR has amino acid (AA) residues 8 to 165 from the extracellular region of the TSHR substituted by the residues 10 to 166
of the LH-CG receptor. The CHO Mc1 + 2 cell line was responsive to
TSH as measured by cAMP induction [57]. In a follow up study the
CHO Mc1 + 2 cell line was compared with a wild type human TSHR
CHO cell line, W25, for the measurement of TBAb [56]. A chimeric
TSHR was also used in a coated tube assay for the detection of TBAb
employing an adaptation of the TSH binding-inhibitory format [58].
This method utilized HEK-293 cells in which the wild-type TSHR of
the TBII assay was exchanged for a chimeric receptor in which supposed TSAb epitopes (AA 8–165) were replaced by a TSH/Luteinizing hormone-choriongonadotropin (LH-CG) residues resulting in
a chimeric receptor (chimera A) [57]. In studies using this assay sera
from patients with GD and AITD were grouped according to their
activity in a TBAb bioassy. At the decision threshold, the chimera
assay had a sensitivity of 78 % for TBAb with a specificity of 90.2 %,
but correlation with the bioassay results was only moderate
(r = 0.46). The technique was purported to allow the differentiation
between sera containing only TBAb, both TBAb and TSAb, only
TSAb, or sera without any bioactivity. Despite such efforts to map
and remove stimulation-specific epitopes and incorporate chimer-
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ic receptors into assays for exclusive detection of TBAb, it is not
clear that these efforts have been successful.

Currently available TSHR-blocking antibody assays
A bioassay is commercially available in Japan (Yamasa, Corp., Chosi,
Chiba, Japan) that utilizes porcine thyroid gland cells for the measurement of TBAb with a cAMP RIA [59, 60]. RSR Limited (Cardiff,
UK) offers a research-use only service to measure TBAb. This assay
uses CHO cells expressing the human TSHR and TBAb is detected
by inhibition of porcine TSH-induced cAMP [61]. In another assay,
autoantibodies inhibit the binding of M22 labeled with biotin to
TSHR-coated enzyme-linked immunosorbent assay (ELISA) plate
wells [62]. Recently, a bioassay for the TBAb measurement based
on luciferase expression was described [23, 25]. The assay uses the
same Mc4 cell line, that is used in the FDA-cleared TSAb bioassay
[22]. The chimeric construct in the Mc4 cells amino acid (AA) residues 262–368 of the human TSHR are substituted with the AA residues 262–334 from the rat LH-CG receptor [25]. There is no cell
line available expressing a modified TSHR that binds exclusively to
TSAb or TBAb including the Mc4 TSHR which was originally purported to have TBAb epitopes removed. The TBAb bioassay using
CHO Mc4 cells was shown to provide excellent analytical performance and a high level of reproducibility [25]. A schematic of the
TBAb bioassay principle is shown in ▶ Fig. 1. Early in the development of this TBAb bioassay, CHO cells expressing either the chimeric human TSHR (Mc4) or the wild-type (wt) TSHR were compared
side by side. Both CHO cell lines were induced with different con-

centrations of bTSH. The half maximal inhibitory concentration of
K1-70 MAb in CHO Mc4 cells was more than five-fold lower compared to the CHO wt cells. The CHO Mc4 cell line showed several
advantages over the CHO wt cell line including a broader linear
range in response to bTSH, higher sensitivity in detecting blocking
activity of the purely human blocking MAb K1-70 as well as detecting higher levels of blocking activity of TBAb positive sera from patients with AITD [23, 25].
Another TSAb/TBAb bioassay was reported that utilizes a unique
cAMP detection method. CHO cells were engineered to express the
TSHR and a calcium-activated bioluminescent protein [63]. Following TSHR activation, increased intracellular cAMP levels activate the
cyclic nucleotide-gated calcium channel. The subsequent influx of
calcium results in bioluminescence of aequorin which is quantified
with a luminometer [63]. As with other TSAb bioassays, TBAb can be
measured with minor modifications of the protocol [63].
▶ Table 2 summarizes first generation (cAMP RIA) and second
generation (cAMP/luciferase) bioassays described for the measurement of TBAb. Although head-to-head comparisons are limited,
the variable methodologies used to detect TBAb do not give identical results and thus it is difficult to compare studies on the prevalence of TBAb [24]. Finally, it is important to note that when sera
contain both TSAb and TBAb, bioassays measure the net activity of
stimulating and blocking antibodies and dilutional analysis of
serum may be required to detect both activities [13, 24]. At the
time of publication there are no TBAb bioassays approved by U.S.
or European regulatory agencies. Although second generation
cAMP and luciferase assays using CHO cells have simplified the TBAb
assay procedure, the availability of TBAb bioassays remains limited. Hopefully, this will change in the near future with increasing
recognition of the importance of TBAb in evaluating and managing patients with AITD.

Clinical Relevance and Clinical
Applications of TBAb
Studies on TBAb in primary hypothyroidism

▶Fig. 1 Schematic of reporter gene-based functional bioassay for
TBAb. CHO cells are engineered to constitutively express the human
TSHR and to express luciferase following induction of cAMP. The
binding of bovine (b) TSH to the TSH receptor on the surface of the
cells induces a signaling cascade that leads to an increase of intracellular cAMP and subsequently to the luciferase expression. However,
the presence of blocking anti-TSHR-Ab (TBAb) in serum of patients
with autoimmune thyroid diseases inhibits the bTSH stimulation of
the luciferase reporter gene. The TBAb level is correlated with blocking activity which is defined as percent inhibition of luciferase expression relative to induction with bTSH alone.
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One of the first studies that identified TBAb in patients with AITD
reported on the inhibition of TSH-induced cAMP increase by IgG
from patients with primary myxedema [29]. IgG fractions prepared
from sera of patients with primary myxedema, goitrous HT, and
controls, respectively, were tested for their ability to alter TSH stimulation of cAMP production in cultured human thyroid cells and the
binding of TSH to its receptor. When compared with the cAMP increase induced by bTSH in the presence of normal IgG, cAMP accumulation was significantly inhibited by IgG from patients with primary myxedema. TSH-induced cAMP accumulation was not affected by IgG from patients with goitrous thyroiditis. These authors
further studied TSH-stimulated cAMP response inhibitory immunoglobulins in patients with atrophic (primary myxedema) and goitrous HT and found TBAb in 40.5 % and 17 % patients with atrophic
and goitrous thyroiditis, respectively [64]. In another study the
prevalence of TBAb was also evaluated in hypothyroid patients with
either goitrous or atrophic thyroiditis [30]. IgG was incubated with
porcine thyroid cells in the presence of bTSH and the results were
Diana T et al. TSHR Blocking Antibodies. Horm Metab Res 2018; 50: 853–862

▶Table 2 First generation (cAMP RIA assays)and second generation (cAMP/luciferase assays) for TSHR blocking autoantibodies.

FIRST generation assays
(cAMP radio-immunoassay)

SECOND generation assays
(cAMP / luciferase)

Year

Species

Assay
time

Comments

Reference

1978

Human

4 days

Human thyroid plasma membranes, adenyl cyclase activity

[51]

1980

Human

4 days

Human thyroid plasma membranes, IgG preparation by column
chromatography through DEAE-Sephadex

[52]

1983

Human

4 days

Thyroid adenoma cells, IgG fractions preparation by DEAE-Sephadex
column chromatography

[29]

1985

Human

4 days

Human thyroid plasma membranes, IgG preparation by DEAE-cellulose
column chromatography

[53]

1987

Rat

4 days

FRTL-5 cells, IgG preparation by DEAE Sephadex

[33]

1989

Rat

1–2 weeks

FRTL-5 cells, IgG preparation by polyethylene glycol (PEG) precipitation

[68]

1989

Rat

1–2 weeks

FRTL-5 cells, IgG extraction by affinity chromatography on columns of
protein A-Sepharose

[66]

1990

Rat

1–2 weeks

FRTL-5 cells, IgG dialyzed in hypotonic buffer

[49]

1999

Porcine

2 days

Porcine thyroid cells, IgG preparation by PEG precipitation

[59]

1999

Hamster

2 days

CHO cells (clones JP02 and JP26)

[73]

2000

Hamster

3 days

CHO cells (clone JP26)

[55]

1994

Hamster

4 days

CHO JP09 cells transfected with the recombinant human TSHR, IgG
dialyzed and diluted in hypotonic buffer

[17]

2001

Hamster

1 day

CHO cells (clone JP09) stably transfected with the TSHR (clone lulu * )

[24]

2004,
2009

Hamster

20–24 h

CHO cells expressing the wild-type human TSHR, use of serum,
spectrophotometric cAMP immunoassay

[62, 83]

2013

Hamster

20 h

Fresh frozen vials of CHO cells expressing the chimeric human TSHR
Mc4 and a luciferase reporter gene, use of serum, luminescence
(cAMP-dependent luciferase expression)

[23, 25, 76]

2015

Hamster

8h

CHO cells expressing the wild-type human TSHR, use of serum, no
sterile conditions necessary, luminescence (cyclic nucleotide-gated
calcium channel and aequorin)

[63]

expressed as the percent inhibition of TSH-stimulated production
of cAMP, as compared with production in a pool of IgG from normal subjects [30]. TBAb were detected in 9 % and 25 % of the patients with goitrous and atrophic thyroiditis, respectively [30]. In a
case report TBAb were detected in a pre-pubertal severely hypothyroid boy (baseline serum TSH 254 mU/l) with atrophic HT and
decreased growth velocity [65].
Potent blocking type anti-TSHR-Ab was observed in the majority
of patients with primary myxedema using a FRTL-5 cell-based bioassay in which the prevalence of TBAb in primary myxedema was
75 % versus 0 % in goitrous HT [66, 67]. In line with this, inhibition of
TSH-stimulated RAI uptake in FRTL-5 cells by crude Ig fractions was
reported for patients with goitrous and atrophic HT as well as from
patients with overt hypothyroidism [16, 68]. TSH-stimulated RAI uptake was inhibited by the Ig fractions from TBII-positive patients with
atrophic thyroiditis due to their TBAb positivity. The mean inhibition
of TSH-stimulated RAI correlated with the ability of the Ig fractions
to inhibit TSAb-stimulated RAI uptake (r = 0.882) and TSH-stimulated cAMP accumulation (r = 0.929) [16]. TBAb were also present in
6/41 (14.6 %) patients with hypothyroidism [68].
Other groups also evaluated Ab blocking the TSH-dependent
cAMP production in FRTL-5 cells [33]. TBAb were evaluated in patients with primary autoimmune hypothyroidism and were detect-

Diana T et al. TSHR Blocking Antibodies. Horm Metab Res 2018; 50: 853–862

able in 15/23 patients with untreated idiopathic myxedema, and
in 2/15 patients under L-T4 treatment. IgG from normal subjects
or from 10 patients with non-autoimmune hypothyroidism did not
cause any significant effect on the TSH-stimulated cAMP production. No correlation was found between TBAb and the thyroid microsomal Ab. These authors further studied the incidence of Ab
blocking the TSH effect in vitro in patients with euthyroid or hypothyroid HT [49]. TBAb were detected in 12/26 (46 %), 1/27 (3 %),
3/32 (9.4 %), and in 20/55 (36 %) patients with atrophic thyroiditis,
euthyroid HT, HT  +  subclinical hypothyroidism, and in hypothyroid
HT, respectively. The prevalence of TBAb was higher in atrophic thyroiditis vs. all other collectives. Mean TBAb levels in atrophic thyroiditis were higher than those in hypothyroid HT and subclinical
HT. An inverse correlation was found between TBAb levels and estimated goiter weight.
The detection of Ab blocking TSH effects using CHO cells transfected with the cloned human TSHR was reported [17]. All IgGs
producing an inhibition greater than two standard deviations from
the mean of controls ( > 25 %) were considered positive for TBAb.
TBAb were detected in 1/8 (12.5 %), 7/30 (23.3 %), and 16/47 (34 %)
patients with subclinical hypothyroid HT, hypothyroid HT and
atrophic thyroiditis, respectively. This group used the same bioassay to demonstrate that humoral thyroid autoimmunity was not
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involved in the pathogenesis of myxedematous endemic cretinism
[69]. Further and unlike TSAb, which are restricted to the IgG1 subclass suggesting an oligoclonal origin, the IgG subclass distribution
of TBAb in primary hypothyroidism are not restricted to a single
subclass and are therefore likely to have a polyclonal origin [70].

Transient TBAb
The often transient nature of TBAb was noted in a report that described
the disappearance of TBAb and the spontaneous recovery from hypothyroidism in a patient with autoimmune thyroiditis [32]. In another
study, 21 TBAb-positive patients were followed for 6–11 years. TBAb
disappeared in 15 patients (group 1), and persisted in six patients
(group 2) [32]. Six patients in group 1 remained euthyroid, and nine
became hypothyroid again within three months [32]. In contrast, all
six patients with persistent TBAb positivity remained hypothyroid [32].
These authors, using a bioassay measuring porcine thyroid cell cAMP
production, reported on their long-term follow-up ( > 10 years) of
TBAb-positive patients with hypothyroidism associated with atrophic
and goitrous thyroiditis [30]. TBAb disappeared in 15/34TBAb-positive patients with hypothyroidism. The disappearance of TBAb correlated with recovery from hypothyroidism in 13 (87 %). All 10 TBAb-positive goitrous patients recovered from hypothyroidism while 19/24
(79 %) TBAb-positive patients with atrophic thyroiditis continued to
be hypothyroid. Two of the 34 TBAb-positive patients with hypothyroidism developed TSAb-positive Graves’ hyperthyroidism. In another study changes in stimulating and blocking Ab were evaluated in a
patient undergoing three cycles of transition from hypo- to hyperthyroidism and back to hypothyroidism [71]. Throughout the entire
course of variation in thyroid function, TSAb were consistently present, but TBAb appeared and disappeared. Monitoring such activity indicated that the emergence of TBAb heralded the onset of hypothyroidism. A change in activity from TSAb to TBAb was also observed in
GD patients during pregnancy and may have contributed to the remission of GD during pregnancy [72]. Median TSAb levels decreased
during pregnancy while TBAb increased. The increase of TBAb was observed among those who were in clinical remission before pregnancy.
A negative correlation was observed between TBAb activity and free
T4 levels during pregnancy.

TBAb in GD
A number of investigators have evaluated the prevalence of TBAb
in GD. One study used CHO cell lines expressing different TSHR
numbers (JP09 and JP26) and found that TBAb were frequently detected in GD [73]. Thirty-four (40 %) of 86 TSAb-negative GD patients were positive for TBAb. Differences between anti-TSHR-Ab
bioactivity and inhibition of radioactive iodine (RAI)-labeled bTSH
binding were noted in that only 78 % of TBAb-positive sera detected with JP26 cells exhibited inhibition of RAI labeled bTSH binding
[74]. Using JP09 CHO cells and unfractionated human serum, TBAb
were detected in 4/24 (17 %) TSAb-negative, TBII-positive hypothyroid GD patients [19]. Blocking type anti-TSHR-Ab were detected
by a radio-receptor bioassay in nine of 30 GD sera (30 %) using unsolubilized porcine TSHR and FRTL-5 cells [75]. In 1079 unselected,
consecutive patients with AITD and 302 healthy controls, TBAb was
found in 4.2 % of patients with GD [76]. Twenty-eight hyperthyroid
GD patients on methimazole were followed for 13 years [77]. Eight
of 28 (29 %) developed TBAb. Patients with TBAb responded well
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initially to ATD and showed earlier normalization of the serum 
T4 level compared to patients without TBAb.

Transplacental transfer of TBAb
In the first report on TBAb in neonatal hypothyroidism, IgGs inhibiting the cAMP response to TSH in human thyroid membranes were
demonstrated in three infants with transient neonatal hypothyroidism suggesting that transplacental transfer of TBAb caused the
hypothyroidism in these infants [78]. Further, transient neonatal
hypothyroidism was found in a daughter of a mother who was receiving treatment for primary hypothyroidism due to HT. IgG from
maternal serum blocked TSH-stimulated cAMP response, and
cAMP-stimulated iodine uptake and organification in cultured thyroid cells [31]. Maternal TBAb were detected in mothers of babies
with either congenital [37] or neonatal [79] hypothyroidism. The
levels of TBAb, based on the ability of patient serum to inhibit TSH
stimulated 3H-cAMP production following incubation of FRTL-5 or
CHO-JPO9 cells with 3H-adenine, decreased to control levels in the
child with neonatal hypothyroidism within two months of birth but
remained elevated in the mother’s serum. Also, an infant with severe neonatal hypothyroidism due to transplacental passage of
TBAb was described [36]. TBAb were detected using a cell line,
which stably expresses the human TSHR and a cAMP-responsive luciferase reporter by their ability to inhibit TSH-stimulated luciferase
expression. High levels of TBAb were detected in maternal serum
and initially in the infant’s serum, but TBAb decreased in the infant
to within the reference range by 3–4 months of age, illustrating the
transient nature of this condition. Surprisingly, the thyroid function of this child did not return to normal on withdrawal of L-T4
therapy at 16 months of age when he developed transient compensated hypothyroidism.

Isolation and in vivo Effects of Human
Blocking Monoclonal Antibodies
Human MAb against the TSHR were isolated from EBV-immortalized B-cells of patients with AITD both to understand the mechanism of the TSHR activation by Ab in patient serum and for the possible development of new treatments [40]. The serum of patients
with AITD contains a mixture of polyclonal Ab whereas it was hypothesized that MAb, by virtue of their binding to a single epitope
on the TSHR, could exhibit either pure stimulating or pure blocking activity in bioassays. This turned out to be the case and there
have been several purely stimulatory and purely blocking MAb reported. Interestingly, a blocking MAb and a separate stimulating
MAb were isolated from the same patient with GD [40].
Two human TSHR blocking MAb 129H8 and 122G3 were isolated from patients with GD that did not exhibit stimulatory activity
in assays of thyroid function, but rather showed blocking activity
in a bioassay [80]. A TSHR blocking MAb, 5C9 was also generated
from the peripheral blood mononuclear cells of a female patient
with post-partum thyroiditis and high serum TBII levels (260 U/l).
This patient’s serum inhibited the stimulating activity of TSH, a
stimulating human MAb (M22), mouse TSHR stimulating MAb and
TSAb from human serum. 5C9 IgG bound with high affinity (4 × 1010
l/mol) to the TSHR and inhibited the binding of TSH and M22 to the
Diana T et al. TSHR Blocking Antibodies. Horm Metab Res 2018; 50: 853–862

receptor. Similar to the patient’s serum, 5C9 IgG preparations inhibited the cAMP stimulating activities of TSH, M22, serum TSAb,
and TSHR-stimulating mouse MAb [81].
The human TSHR blocking MAb K1-70 was isolated in 2010 [40].
B cells were obtained from the peripheral blood of a 54-year old
woman with hypothyroidism and elevated TBII (160 U/l). The patient
had an eight year history of AITD and she initially presented with hyperthyroidism, which was treated with methimazole. She then developed hypothyroidism and received levothyroxine. Evaluation of
her serum showed both TSAb and TBAb with stimulating activity
seen up to a dilution of 1/100 and blocking activity of 82 % inhibition
at 1/10 dilution. Lymphocytes were infected with EBV and fused with
a mouse/human hybrid cell line (K6H6/B5). Using a TBII assay supernatants of twelve thousand hybridoma clones were screened to identify the K1-70 clone which stably expresses around 40 mg/l of IgG.
K1-70 IgG was purified from culture supernatants using protein A
affinity chromatography. K1-70 inhibited cAMP induction by TSH, a
stimulating MAb, and TSAb-positive sera in TSHR-expressing CHO
cells [40]. K1-70 IgG1 lambda showed high binding affinity (4 × 1010
l/mol) to the TSHR and bound to leucine-rich repeats 1–10 [82]. Furthermore, K1-70 was able to inhibit the stimulating activity of M22
in CHO cells expressing the human TSHR [82].
Human MAb produced against the TSHR were utilized to study
their effects in vivo in laboratory animals [83, 84]. K1-70 was a potent inhibitor in vivo and was able to block the stimulating activity
of M22. Furthermore K1-70 inhibited thyroid hormone secretion
in rats following the intramuscular injection of 10–200 μg per animal [84]. In rats treated with K1-70 alone, the total T4 and free T4
decreased in a dose-dependent manner. These results demonstrate
that the activity of these MAb observed in bioassays correlates with
their in vivo activities. Further, it provides strong evidence that the
bioassays in which the activity of these anti-TSHR MAb were measured, though contrived for convenient measurement, are nevertheless physiologically relevant.

Clinical Indications for TBAb and
Concluding Remarks
Our laboratory uses a TBAb bioassay based on the CHO/Mc4 luciferase cells used in an FDA-cleared TSAb assay. When evaluating
serum samples of approximately 2000 unselected, consecutive patients with AITD, seen and followed at our institution, TBAb were
prevalent in both subjects with HT (11 %) as well as in those with GD
(8 %). The results of the TBAb measurement in the first 1400 patients
have been reported [25, 76]. It is becoming clear that in addition to
the well-known T-cell-mediated cytotoxicity and the involvement of
CDC in HT, thyroid dysfunction and hypothyroidism can be induced
by the occurrence and presence of TBAb. We and others have noted
the occurrence of TBAb in patients with GD post radioactive iodine
therapy and/or during treatment with antithyroid drugs [85], in patients with HT of recent onset, in AITD during pregnancy, as well as
patients with non-thyroidal autoimmune disorders, that is, type 1
diabetes [38, 86–89]. The occurrence of TBAb during or after antithyroid drug treatment can impact the course of GD with TBAb-positive
patients going into early remission or becoming spontaneously hypothyroid [85, 88]. Also, the majority of TBAb-positive subjects with
Diana T et al. TSHR Blocking Antibodies. Horm Metab Res 2018; 50: 853–862

▶Table 3 Potential indications for the measurement of thyrotropin
receptor blocking antibodies.
1.
2.
3.
4.
5.
6.
7.
8.
9.

 raves‘ disease: post radioactive iodine treatment and/or during
G
therapy with antithyroid drugs
Autoimmune Hashimoto‘s thyroiditis
Autoimmune thyroid disease in pregnancy
Neonatal hypothyroidism
Postpartum thyroid disease
Differential diagnosis of thyroiditis
Differential diagnosis of hypothyroidism
Down Syndrome *
Non-thyroidal autoimmune diseases (SLE, RA, type 1 diabetes,
myasthenia)

*  According to reference [92]; SLE: Systemic lupus erythematodus,
RA: Rheumatoid arthritis.

▶Fig. 2 Diagnostic flowchart for TSHR blocking antibody-induced
hypothyroidism.

HT were hypothyroid in contrast to TBAb-negative subjects who were
predominantly euthyroid [76]. Regarding pregnancy and AITD, there
is a real risk for the fetus in pregnant women with TSHR autoantibodies since both stimulating and blocking anti-TSHR-Ab can cross the
placenta. Further, the risk for fetal/infant hyper- and hypothyroidism
correlates with TSAb/TBAb levels [90, 91]. Therefore, and as listed in
▶Table 3, there are several potential clinical indications for the measurement of TBAb in patients with AITD. Further, and as illustrated in
▶Fig. 2, in patients with abnormally elevated basal serum TSH and
suspected AITD, the measurement of TBAb can help diagnose humoral immunity-induced hypothyroidism in which thyroid dysfunction is caused by TBAb. However, and as previously acknowledged in
the introduction, when compared to the abundant literature pertaining to the clinical applications of TSAb, more prospectively designed, controlled studies are warranted to gain more insight and
daily experience regarding both the clinical utility of measuring TBAb
as well as their potential implications for diagnosis, differential diagnosis, management and follow-up of patients with AITD.
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